Risk factors for SVT
| . | No. of patients (n = 100) . |
|---|---|
| Risk factors | |
| Unprovoked, n (%) | 43 (43.0) |
| Multiple risk factors, n (%) | 5 (5.0) |
| Abdominal inflammation/infection, n (%) | 28 (28.0) |
| Solid cancer, n (%) | 9 (9.0) |
| Overt myeloproliferative neoplasm, n (%) | 9 (9.0) |
| Recent abdominal surgery, n (%) | 7 (7.0) |
| Estrogen hormonal therapy, n (%) | 9 (9.0) |
| Thrombophilia and JAK2 V617F mutation testing | |
| Factor V Leiden mutation, n/N tested (%) | 3/42 (7.1) |
| Prothrombin G20210A mutation, n/N tested (%) | 9/39 (23.1) |
| Protein C deficiency, n/N tested (%) | 2/27 (7.4) |
| Protein S deficiency, n/N tested (%) | 1/27 (3.7) |
| Antithrombin deficiency, n/N tested (%) | 1/26 (3.9) |
| Hyperhomocysteinemia, n/N tested (%) | 4/25 (16.0) |
| Lupus anticoagulant, n/N tested (%) | 2/29 (6.9) |
| Anti-cardiolipin antibodies, n/N tested (%) | 1/34 (2.9) |
| Anti-β-2-glycoprotein I, n/N tested (%) | 0/33 (0) |
| JAK2 V617F mutation, n/N tested (%) | 13/50 (26.0) |
| . | No. of patients (n = 100) . |
|---|---|
| Risk factors | |
| Unprovoked, n (%) | 43 (43.0) |
| Multiple risk factors, n (%) | 5 (5.0) |
| Abdominal inflammation/infection, n (%) | 28 (28.0) |
| Solid cancer, n (%) | 9 (9.0) |
| Overt myeloproliferative neoplasm, n (%) | 9 (9.0) |
| Recent abdominal surgery, n (%) | 7 (7.0) |
| Estrogen hormonal therapy, n (%) | 9 (9.0) |
| Thrombophilia and JAK2 V617F mutation testing | |
| Factor V Leiden mutation, n/N tested (%) | 3/42 (7.1) |
| Prothrombin G20210A mutation, n/N tested (%) | 9/39 (23.1) |
| Protein C deficiency, n/N tested (%) | 2/27 (7.4) |
| Protein S deficiency, n/N tested (%) | 1/27 (3.7) |
| Antithrombin deficiency, n/N tested (%) | 1/26 (3.9) |
| Hyperhomocysteinemia, n/N tested (%) | 4/25 (16.0) |
| Lupus anticoagulant, n/N tested (%) | 2/29 (6.9) |
| Anti-cardiolipin antibodies, n/N tested (%) | 1/34 (2.9) |
| Anti-β-2-glycoprotein I, n/N tested (%) | 0/33 (0) |
| JAK2 V617F mutation, n/N tested (%) | 13/50 (26.0) |